Skip to main content

GeneLink Raises $2.4M in Private Placements

NEW YORK (GenomeWeb News) – GeneLink today said that it has raised $2.4 million through two private placements of its stock.

The consumer genomics firm said that it closed the first placement in January and the second one on Feb. 27. According to the firm's CEO, Monte Taylor, funding came from shareholders of GeneLink, which is publicly traded on the OTC Bulletin Board, marketing affiliates of GeneWize Life Sciences, and "arms-length" financial investors.

GeneWize is a wholly owned subsidiary of Orlando, Fla.-based GeneLink and is focused on marketing nutritional supplements and skincare products specifically tailored to an individual's genetic makeup.

Taylor said in a statement that the funds from the private placements would be used to "upgrade the infrastructure of GeneWize to enable us to support the anticipated demand for our products and services."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.